For healthcare professionals only

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​
The media partners for this activity are GPnotebook and Diabetes on the net. GPnotebook and Diabetes on the net have had no input into the content of this website.

Prescribing information for United Kingdom and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

Focus on: Ramadan

It is important to conduct a pre-Ramadan assessment 6-8 weeks prior to Ramadan for adults with diabetes who wish to undertake fasting during this time1

Did you know?

In a study of 12,529 Muslims with type 2 diabetes, 85.1% fasted during Ramadan despite being exempt due to their medical condition2

What should I do next?

If an adult with type 2 diabetes in your clinic still wishes to fast despite being exempt due to their medical condition, consider the below resources from Alia Gilani that explore the steps to best support these people

Healthcare professional resources

Alia Gilani

Click here to view video

A case-based approach to the practical management of type 2 diabetes during Ramadan and periods of fasting: A summary

  • Fundamentals of Ramadan and risks associated with fasting for people living with type 2 diabetes
  • Goals of care and guidance on medication adjustments during Ramadan
  • Case-based examples to to explore strategies for manging type 2 diabetes during Ramadan
  • This 2-page fact sheet summarises the key information from the video to help you best support people with type 2 diabetes who wish to fast during Ramadan

Leaflet to share with your patients

Alia Gilani

Supporting your patients during Ramadan

  • This leaflet, designed for patients, outlines the key considerations a person with diabetes should be aware of when planning to fast during Ramadan, and a medication change tracker
  • Includes a link to a patient video discussing considerations prior to Ramadan fasting

Developed by Alia Gilani,
Pharmacist with a Special Interest in Diabetes
and Cardiometabolic Disease

Alia Gilani is a specialist pharmacist whose interests lie in ethnic inequalities, diabetes and cardio-metabolic disease. She helped establish and run a bilingual medication review service in NHS Glasgow called the Minority Ethnic Long-Term (MELT) medicines service, which operated for over a decade and was recognised with awards at the local and national level.

Alia runs outreach clinics for South Asian individuals with diabetes and cardio-metabolic disease in various locations, including mosques and elderly care centres. She was a member of the diabetes working group for the South Asian Health Foundation for 13 years, and is now an appointed trustee of the foundation. She was the first pharmacist to become a member of the Primary Care Diabetes and Obesity Society committee, a position she held for 7 years, and she currently sits on the Diabetes UK Professional Conference organising committee.

References:

  1. International Diabetes Federation. Diabetes and Ramadan Practical Guidelines. 2021. Available at: https://idf.org/media/uploads/2024/07/IDF_DaR_Practical_Guidelines_Ramadan.pdf (accessed November 2025).
  2. Hassanein M, et al. Curr Med Res Opin. 2024;40(9):1515–1523.

Sarah Jarvis
Webinar Series Chair

Watch the most recent webinar

Initiated and funded by Boehringer Ingelheim

PC-GB-110175 | July 2024

Prescribing information for the United Kingdom and Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

PC-GB-106628 V7 | November 2025

PC-GB-110742 V2 | November 2025

Trajenta® (linagliptin) prescribing information: UK and ROI.

JARDIANCE® (empagliflozin) prescribing information: UK and ROI.

This website is for healthcare professionals in the United Kingdom and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in the United Kingdom or the Republic of Ireland by clicking below.

Quick questionnaire

Prescribing information for the United Kingdom and the Republic of Ireland 

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.